​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories (CRL) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $206.43, with a high of $220.00 and a low of $185.00. This represents a 16.22% increase from the last price of $177.62.

$175 $195 $215 $235 $255 $275 High: $220 Avg: $206.43 Low: $185 Last Closed Price: $177.62

CRL Stock Rating

Charles River Laboratories stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 1 Strong Buy (2.78%), 24 Buy (66.67%), 11 Hold (30.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 11 24 1 Strong Sell Sell Hold Buy Strong Buy

CRL Price Target Upside V Benchmarks

TypeNameUpside
StockCharles River Laboratories16.22%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks30.89%

Price Target Trends

1M3M12M
# Anlaysts6921
Avg Price Target$211.67$204.22$206.29
Last Closing Price$177.62$177.62$177.62
Upside/Downside19.17%14.98%16.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 262104-117
Apr, 261106--17
Mar, 261107--18
Feb, 261107--18
Jan, 261107--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 08, 2026Eric ColdwellRobert W. Baird$213.00$175.5621.33%19.92%
May 08, 2026Evercore ISI$220.00$176.3224.77%23.86%
May 08, 2026Mizuho Securities$192.00$181.685.68%8.10%
May 08, 2026Luke SergottBarclays$220.00$181.6821.09%23.86%
Apr 14, 2026Luke SergottBarclays$210.00$178.3417.75%18.23%
Apr 14, 2026RBC Capital$215.00$178.3420.56%21.04%
Feb 20, 2026Mizuho Securities$175.00$164.246.55%-1.48%
Feb 19, 2026Eric ColdwellRobert W. Baird$193.00$158.1822.01%8.66%
Feb 19, 2026Luke SergottBarclays$200.00$158.0026.58%12.60%
Jan 13, 2026Robert W. Baird$231.00$221.694.20%30.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 08, 2026Evercore ISIOutperformOutperformhold
May 08, 2026BarclaysOverweightOverweighthold
Apr 14, 2026BarclaysOverweightOverweighthold
Apr 14, 2026RBC CapitalOutperforminitialise
Apr 08, 2026Evercore ISIOutperformOutperformhold
Feb 20, 2026Cowen & Co.BuyBuyhold
Feb 19, 2026BarclaysOverweightOverweighthold
Jan 22, 2026Cowen & Co.BuyBuyhold
Jan 16, 2026CitigroupBuyBuyhold
Jan 13, 2026Evercore ISIOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $0 $5 $10 $15 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.77$9.57$9.27$0.20$-2.91---
Avg Forecast$10.26$10.89$10.59$10.19$9.88$11.00$12.43$14.23
High Forecast$10.51$11.15$10.68$10.30$12.56$12.63$15.07$15.26
Low Forecast$9.96$10.70$10.45$10.12$9.10$9.71$10.39$13.52
Surprise %-24.27%-12.12%-12.46%-98.04%-129.45%---

Revenue Forecast

$3B $3B $4B $4B $5B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.54B$3.98B$4.13B$4.05B$4.02B---
Avg Forecast$3.52B$3.91B$4.11B$4.03B$3.93B$4.16B$4.37B$4.63B
High Forecast$3.59B$3.98B$4.12B$4.05B$4.07B$4.18B$4.42B$4.89B
Low Forecast$3.44B$3.86B$4.10B$4.02B$3.77B$4.15B$4.31B$4.46B
Surprise %0.50%1.64%0.55%0.47%2.23%---

Net Income Forecast

$-150M $40M $230M $420M $610M $800M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$390.98M$486.23M$474.62M$10.30M$-144.34M---
Avg Forecast$364.08M$454.69M$474.62M$525.43M$557.17M$574.85M$654.91M$732.15M
High Forecast$436.89M$545.62M$569.55M$530.07M$646.04M$650.02M$775.34M$785.01M
Low Forecast$291.26M$363.75M$379.70M$520.79M$468.30M$499.69M$534.47M$695.76M
Surprise %7.39%6.94%--98.04%-125.91%---

CRL Forecast FAQ

Is Charles River Laboratories stock a buy?

Charles River Laboratories stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 24 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Charles River Laboratories is a favorable investment for most analysts.

What is Charles River Laboratories's price target?

Charles River Laboratories's price target, set by 36 Wall Street analysts, averages $206.43 over the next 12 months. The price target range spans from $185 at the low end to $220 at the high end, suggesting a potential 16.22% change from the previous closing price of $177.62.

How does Charles River Laboratories stock forecast compare to its benchmarks?

Charles River Laboratories's stock forecast shows a 16.22% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (30.89%).

What is the breakdown of analyst ratings for Charles River Laboratories over the past three months?

  • May 2026: 11.76% Strong Buy, 58.82% Buy, 23.53% Hold, 0% Sell, 5.88% Strong Sell.
  • April 2026: 5.88% Strong Buy, 58.82% Buy, 35.29% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 5.56% Strong Buy, 55.56% Buy, 38.89% Hold, 0% Sell, 0% Strong Sell.

What is Charles River Laboratories’s EPS forecast?

Charles River Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $11, marking a -478.01% decrease from the reported $-2.91 in 2025. Estimates for the following years are $12.43 in 2027, and $14.23 in 2028.

What is Charles River Laboratories’s revenue forecast?

Charles River Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $4.16B, reflecting a 3.68% increase from the reported $4.02B in 2025. The forecast for 2027 is $4.37B, and $4.63B for 2028.

What is Charles River Laboratories’s net income forecast?

Charles River Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $574.85M, representing a -498.27% decrease from the reported $-144M in 2025. Projections indicate $654.91M in 2027, and $732.15M in 2028.